Form 4: Cogent Biosciences CSO Reports Significant Equity Awards

Cogent Biosciences' Chief Scientific Officer, John Edward Robinson, reported the acquisition of 370,000 shares of common stock and 65,000 stock options, alongside the surrender of 139,998 shares for tax withholdings.

Summary

• John Edward Robinson, Chief Scientific Officer of Cogent Biosciences, Inc., reported several transactions on December 17, 2025.
• Acquired 50,000 shares of common stock through an award of Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan.
• Acquired 320,000 shares of common stock due to the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").
• Disposed of 139,998 shares of common stock at a price of $39.45 per share to cover required tax withholdings related to the vesting of the 2023 PSUs.
• Acquired 65,000 stock options (Right to Buy) with an exercise price of $39.45 per share and an expiration date of December 17, 2035.
• Following these transactions, Mr. Robinson beneficially owns 230,002 shares of common stock (including RSUs subject to vesting) and 65,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The filing details routine executive compensation, including significant equity awards and the vesting of performance-based units, which generally indicates stability and ongoing executive alignment with company performance. The disposition for tax purposes is a neutral, expected event.

Positives

• Grant of 50,000 Restricted Stock Units (RSUs) to the Chief Scientific Officer, indicating ongoing compensation and retention.
• Vesting of 320,000 performance-based RSU shares, demonstrating achievement of prior performance targets.
• Grant of 65,000 stock options, providing long-term incentive aligned with shareholder interests.

Negatives

• Disposition of 139,998 shares of common stock to satisfy tax withholding obligations, which reduces direct share ownership.

Future Outlook

The newly awarded Restricted Stock Units (RSUs) will vest with respect to 1/4th of the underlying shares on each anniversary of the grant date over four years, contingent on continuous service. The granted stock options will vest in equal monthly installments over a four-year period, also subject to continuous service to the Issuer.

Industry Context

This filing represents routine executive compensation and retention activities within the biotechnology or pharmaceutical industry, where equity awards are a standard component of executive pay packages. The vesting of performance-based units suggests the company met certain pre-defined operational or financial milestones, common in a sector focused on long-term development and regulatory approvals.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a significant component of executive compensation is standard practice across the biotechnology and pharmaceutical industries, aligning executive incentives with long-term shareholder value.
• The four-year vesting schedule for both RSUs and stock options is a common industry benchmark for executive equity awards, designed to promote long-term retention and performance.
• The surrender of shares for tax withholding upon vesting is a routine and expected event for equity compensation in the U.S., consistent with practices at comparable companies like Moderna (MRNA) or BioNTech (BNTX) when their executives' equity awards vest.

Stakeholder Impact

• Shareholders: The grant of equity awards to a key executive aligns management's interests with shareholder value creation over the long term. The vesting of performance-based units suggests prior company performance met targets, which is positive for shareholders.
• Employees: The compensation structure for the Chief Scientific Officer may reflect broader compensation philosophies within the company, potentially impacting employee morale and retention strategies.

Next Steps

• The RSUs awarded on December 17, 2025, will vest 1/4th annually on each anniversary of the grant date over four years.
• The stock options granted on December 17, 2025, will vest in equal monthly installments over a four-year period.

Key Dates

Keywords

Cogent Biosciences, COGT, Form 4, Insider Transaction, Restricted Stock Units, RSUs, Performance Stock Units, PSUs, Stock Options, Executive Compensation, Beneficial Ownership